02 新冠疫苗成功，BioNTech宣布回報股東

BioNTech plans to return €2bn to shareholders through share buybacks and a special dividend following the commercial success of its Covid-19 vaccine, the company said on Wednesday.

BioNTech周三宣布擬通過股票回購和特別股息向股東返還20億歐元，此前該公司的新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒?。┮呙缛〉蒙虡I成功。

The German biotech, which launched the first Covid-19 vaccine in partnership with Pfizer, said it would also boost research and development spending by 50 per cent to €1.4bn to €1.5bn, as it seeks to develop a new range of drugs based on mRNA technology.

與輝瑞（Pfizer）聯手推出首款COVID-19疫苗的這家德國生物技術公司表示，它還將把研發支出增加50%，達到14億至15億歐元。該公司正致力于開發一系列基于mRNA技術的新藥。

“To continue our industry leadership, we intend to build on our 2021 success and rapidly advance multiple programs, including our mRNA-based immunotherapies, cell therapies, and bi-specific antibodies,” said Ugur Sahin, BioNTech’s co-founder and chief executive.

“為了繼續保持行業領先地位，我們打算在2021年成功的基礎上再接再厲，快速推進多項計劃，包括我們基于mRNA的免疫療法、細胞療法和雙特異性抗體，”BioNTech聯合創始人和首席執行官烏格·沙欣（Ugur Sahin）表示。